Status:
COMPLETED
Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients
Lead Sponsor:
Mario Boccadoro
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for individual Multiple Myeloma (MM) patients. MM is the second...
Eligibility Criteria
Inclusion
- The bio-banked MM patient samples and clinical data will be obtained from previous European clinical trials that have been conducted over the past 5 years within the participating clinical centres and other clinical centers. The samples were not collected for the purposes of this project. The subjects from which the data was initially taken cannot be identified from the data/records. However, the patients from the above mentioned trial have explicitly consented for the use of their samples for other (future) clinical research purposes.
Exclusion
- \-
Key Trial Info
Start Date :
June 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2022
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT03409692
Start Date
June 14 2017
End Date
July 25 2022
Last Update
June 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Turin
Turin, Italy, 10125